ADURO BIOTECH, INC.

Form 4

January 13, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer

subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005 Estimated average

OMB APPROVAL

burden hours per

response...

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

Common

Stock

(Print or Type Responses)

01/11/2017

1. Name and A Templemar	Address of Reporting n Blaine	Sym	2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ADRO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (I		3. Date of Earliest Transaction							
		(Mo	nth/Day/Year)			Director	10%	Owner		
C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE			1/2017			_X_ Officer (give below) Executive	below) e VP, General Co			
(Street)			Amendment, D	ate Origina	1	6. Individual or Joint/Group Filing(Check				
		Filed	l(Month/Day/Yea	r)		Applicable Line) _X_ Form filed by	One Reporting Pe More than One Re			
BERKELE	Y, CA 94710					Person	wiore than One Re	porting		
(City)	(State)	(Zip)	Table I - Non-	Derivative	Securities Acc	quired, Disposed of, or Beneficially Owned				
1.Title of	2. Transaction Date	e 2A. Deemed	3.	4. Securi	ties Acquired	5. Amount of	6. Ownership	7. Nature of		
Security	(Month/Day/Year)	Execution Date	e, if Transacti	on(A) or Di	sposed of (D)	Securities	Form: Direct	Indirect		
(Instr. 3)		any	Code	Code (Instr. 3, 4 and 5)			(D) or	Beneficial		
		(Month/Day/Y	ear) (Instr. 8)			Owned	Indirect (I)	Ownership		
						Following	(Instr. 4)	(Instr. 4)		
					(A)	Reported				
					or	Transaction(s)				
			Code V	Amount	(D) Price	(Instr. 3 and 4)				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $S_{\underline{(1)}}$

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

37,300 (2)

D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3,785

Edgar Filing: ADURO BIOTECH, INC. - Form 4

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exer	cisable and	7. Title	and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orNumber	Expiration D	ate	Amour	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underl	ying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securit	ies	(Instr. 5)	Bene
	Derivative				Securities			(Instr. :	3 and 4)		Owne
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									A		
									Amount		
						Date	Expiration		or		
						Exercisable	Date		Number		
				~					of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Templeman Blaine C/O ADURO BIOTECH, INC. 740 HEINZ AVENUE BERKELEY, CA 94710

Executive VP, General Counsel

Signatures

/s/ Jennifer Lew, Attorney-in-Fact 01/13/2017

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2016.
- (2) Includes 1,621 shares and 584 shares acquired by the Reporting Person under the Issuer stock purchase plan on May 13, 2016 and November 15, 2016, respectively.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2